Serious drug-induced liver injury, including acute liver failure, hepatitis and jaundice, have been observed with the biologic tocilizumab (Actemra), according to the Therapeutic Goods Administration (TGA) In an advisory statement to health professionals, the TGA says serious hepatotoxicity is considered rare, but in some cases treatment has required liver transplant. Tocilizumab is approved for use ...
Liver toxicity warning for tocilizumab
By Michael Woodhead
12 Jul 2019